Literature DB >> 23902543

Challenges of creating effective chimeric antigen receptors for cancer therapy.

Charles L Sentman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23902543      PMCID： PMC3881530          DOI： 10.2217/imt.13.71

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  19 in total

1.  T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors:  Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

2.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 3.  Treating cancer with genetically engineered T cells.

Authors:  Tristen S Park; Steven A Rosenberg; Richard A Morgan
Journal:  Trends Biotechnol       Date:  2011-06-12       Impact factor: 19.536

4.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Authors:  Xiuli Wang; Wen-Chung Chang; ChingLam W Wong; David Colcher; Mark Sherman; Julie R Ostberg; Stephen J Forman; Stanley R Riddell; Michael C Jensen
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Authors:  Barbara Savoldo; Carlos Almeida Ramos; Enli Liu; Martha P Mims; Michael J Keating; George Carrum; Rammurti T Kamble; Catherine M Bollard; Adrian P Gee; Zhuyong Mei; Hao Liu; Bambi Grilley; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

6.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Authors:  Anna Kruschinski; Andreas Moosmann; Isabel Poschke; Håkan Norell; Markus Chmielewski; Barbara Seliger; Rolf Kiessling; Thomas Blankenstein; Hinrich Abken; Jehad Charo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

7.  Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.

Authors:  Tong Zhang; Amorette Barber; Charles L Sentman
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

8.  Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.

Authors:  Amorette Barber; Tong Zhang; Charles L Sentman
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

9.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

10.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245
View more
  3 in total

Review 1.  Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.

Authors:  M A Kharfan-Dabaja; W G Wierda; L J N Cooper
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

2.  Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors.

Authors:  Alexandra L Martin; Carmen M Anadon; Subir Biswas; Jessica A Mine; Katelyn F Handley; Kyle K Payne; Gunjan Mandal; Ricardo A Chaurio; John J Powers; Kimberly B Sprenger; Kristen E Rigolizzo; Patrick Innamarato; Carly M Harro; Sumit Mehta; Bradford A Perez; Robert M Wenham; Jose R Conejo-Garcia
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

Review 3.  NKG2D CARs as cell therapy for cancer.

Authors:  Charles L Sentman; Kenneth R Meehan
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.